The TGA has rejected a bid to improve access to a medical cannabis spray for MS spasticity symptoms by down-scheduling it from Schedule 8 to Schedule 4 status. The nabiximols oromucosal spray (Sativex) is licensed by the TGA as a prescription (Schedule 8) medicine for the treatment of adults with spasticity due to multiple sclerosis, ...
S8 restrictions to remain on medical cannabis spray for MS spasticity
By Michael Woodhead
14 Mar 2019